STOCKS TO BUY: We have identified several stocks that can potentially TRIPLE. Learn more!

Arthritis Therapeutics Market To 2018 - Novel Oral JAK Inhibitors And Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Table 28: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2004-2010 56

Table 29: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018 56

Table 30: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 57

Table 31: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 57

Table 32: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 58

Table 33: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 59

Table 34: Ankylosing Spondylitis Therapeutics-Marketed Products, 2010 60

Table 35: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2010 63

Table 36: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018 63

Table 37: Arthritis Therapeutics Market, The US, Revenue ($bn), 2004-2010 64

Table 38: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2018 64

Table 39: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2004-2010 65

Table 40: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2010-2018 65

Table 41: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2010 66

Table 42: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018 66

Table 43: Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2004-2010 68

Table 44: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2018 68

Table 45: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2010 69

Table 46: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2010-2018 69

Table 47: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2010 70

Table 48: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2010-2018 71

Table 49: Arthritis Therapeutics Market, Japan, Revenue ($bn), 2004-2010 72

Table 50: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2018 72

Table 51: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2010 73

Table 52: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018 73

Table 53: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2010 74

Table 54: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018 74

Table 55: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 79

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
TRY IT FREE
New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,112.19 -206.04 -1.35%
NASDAQ 3,443.20 -38.98 -1.12%
S&P 500 1,628.93 -22.88 -1.39%
US 10 Yr 2.311% +0.129

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs